Navigation Links
BellBrook Labs Launches Ultra-Sensitive Methyltransferase Assay to Accelerate Epigenetic Drug Discovery
Date:8/10/2017

BellBrook Labs announces the launch of their latest drug discovery tool, the AptaFluor SAH Methyltransferase Assay, an enabling new high throughput screening (HTS) assay to aid researchers in their search for breakthrough drugs targeting epigenetic pathways that drive cancer and other debilitating diseases.

Chemical modification of gene expression, also known as epigenetics, is perhaps the most promising area for molecularly targeted drug discovery since validation of kinases as drug targets. Methyltransferases are the largest class of epigenetic enzymes, and several have been shown to play a causative role in cancer and other diseases. Several years ago, major drug discovery efforts were initiated using HTS to identify methyltransferase inhibitors, much like the successful approach used for protein kinases. However, due to their intrinsic properties, detection of methyltransferase activity requires extremely sensitive radioactive assays and/or large amounts of methyltransferase enzymes, which made HTS impractical in many instances. For these reasons, there has been a long-standing need for more sensitive, non-radioactive assays to enable robust, cost effective screening of methyltransferase targets.

As a first-of-its-kind homogeneous assay using aptamers (nucleic acid-based affinity reagents) for HTS, the AptaFluor SAH Methyltransferase Assay provides an elegant solution to the cost and sensitivity barriers that were hampering the discovery of methyltransferase inhibitors. Methyltransferases produce a variety of methylated products, but all use S-adenosylmethionine (SAM) as the methyl donor, leaving S-adenosylhomocysteine (SAH) as a common reaction product. The AptaFluor SAH Assay is based on a naturally occurring microbial aptamer, discovered by Yale University professor Ron Breaker, which evolved to recognize SAH with exquisite sensitivity and selectivity.

BellBrook scientists engineered the SAH aptamer to produce a fluorescent signal on binding to SAH, resulting in a non-radioactive assay with unparalleled sensitivity. By directly detecting SAH, the new AptaFluor assay is universal, allowing the researcher to use the assay for virtually any methyltransferase enzyme. The assay utilizes a simple mix-and-read format with a far red positive TR-FRET readout, ensuring its compatibility with automated dispensing equipment and plate readers commonly used for HTS. With this novel assay technology, scientists can now more easily study challenging methyltransferase targets with the efficiency demanded by today’s drug discovery programs.

About BellBrook Labs

BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions. BellBrooks core technology Transcreener® is a universal, homogeneous biochemical assay platform based on detection of nucleotides that makes it easy to screen thousands of different enzymes. These include validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. Detection reagents and drug discovery services from BellBrook Labs help researchers progress toward more effective therapies for cancer and other debilitating diseases.

Read the full story at http://www.prweb.com/releases/New-Methyltransferase/HTS-Assay/prweb14582831.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services
2. BellBrook Labs Webinar on July 22nd: Simplifying HTS with Orthogonal Pooled Screening
3. BellBrook Labs Teams Up with UW-Madison to Fight Neurodegenerative Diseases using Stem Cells and Microfluidics
4. BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay
5. BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening
6. BellBrook Labs Webinar: Transcreener® HTS assays for UDP, GDP, and CMP as a Universal Glycosyltransferase Assay Platform
7. BellBrook Labs and UW-Madison Team Awarded NCI Contract to Develop Next Generation Cancer Models
8. BellBrook Labs Develops a TR-FRET Based Transcreener GTPase Assay
9. BellBrook Labs Seeking Partners to Accelerate Commercialization of Innovative HTS Assay Technologies
10. BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2
11. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
Breaking Biology News(10 mins):